查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1916509

全球獸藥市場：市場規模、份額、成長率、產業分析、按類型、應用和地區劃分的考量因素以及未來預測（2026-2034）

Veterinary Therapeutics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 210 Pages | 商品交期: 請詢問到貨日

價格

獸藥市場成長驅動因素

預計2025年全球獸藥市場規模將達到472.5億美元，2026年將成長至496.5億美元，到2034年將達到815.9億美元。預計在預測期內（2026-2034年），其複合年增長率（CAGR）為6.40%。北美地區引領全球獸藥市場，預計2025年將佔40.02%的市場。這主要得益於北美地區較高的寵物擁有率、完善的動物照護基礎設施以及先進的畜牧養殖技術。

獸藥市場包括用於預防、治療和改善伴侶動物和牲畜生產性能的藥品、疫苗和含藥飼料添加劑。該市場在控制人畜共患病、維護食品安全和改善動物福利方面發揮關鍵作用。

市場驅動因素

寵物飼養量和獸醫保健支出的成長是主要驅動因素。預計到2024年，美國犬隻數量將達到5,980萬隻，貓的數量將達到4,220萬隻，平均每個家庭每年在犬隻和貓身上的支出分別為580美元和433美元，這將推動對預防性和慢性病藥物的需求。

為滿足不斷增長的全球蛋白質需求而擴大畜牧業規模也促進了市場成長。根據世界動物衛生組織（OIE）統計，全球77.0%的牲畜受到口蹄疫的影響，這將推動對疫苗和早期疾病管理的需求。寄生蟲感染、牛乳腺炎、犬小病毒和蜱傳疾病病例的增加進一步推動了對治療的需求。

新產品的推出持續推動成長。 2024年9月，Eleanco公司的Zenrelia獲得FDA批准，這是一種用於治療犬過敏性皮膚炎的每日一次口服藥物，標誌著伴侶動物治療領域的創新取得了進展。

市場限制因子

因副作用或安全問題導致的產品召回可能會削弱消費者信心。 2021年6月，英國一家獸藥藥局因安全問題召回了Seba公司的Salmovac 400疫苗。 2023年12月，澳洲在收到包括致命病例在內的嚴重副作用報告後，召回了犬隻用Tridoria Auslepto疫苗。此類事件可能導致品牌聲譽受損和監管審查加劇，進而抑制市場成長。

市場機會

研發投入和監管審批正在創造成長機會。 2024年4月，FDA批准了Pradarex注射液用於治療牛和豬的呼吸道疾病，從而擴大了畜牧業疾病管理的選擇。對先進生物製劑和標靶療法的日益重視，在提高安全性的同時，也為疾病管理提供了支持。

農民和寵物主人對預防保健意識的提高，也推動了疫苗接種計劃和早期診斷的普及，從而擴大了新興經濟體的市場潛力。

市場挑戰

抗菌素抗藥性（AMR）是一個重大挑戰，尤其是在抗生素濫用普遍存在的低收入農業地區。 2024年9月，世界動物衛生組織（OIE）估計，到2025年，抗菌素抗藥性可能導致全球醫療保健成本增加1,890億美元。更嚴格的抗生素監管限制了藥物的供應，影響了畜牧業生產力，阻礙了治療藥物市場的成長。

市場趨勢

基因療法和細胞療法正成為獸醫學領域新興的創新治療方法。 2024年12月，Protect Animal Health與Rejuvenate Bio合作開發PT-401，一種用於治療犬二尖瓣疾病的基因療法。這標誌著動物醫療正朝著個人化方向發展。

此外，新冠疫情期間遠距醫療的普及擴大了處方藥的取得途徑和慢性病監測的覆蓋範圍，進一步推動了治療藥物的銷售。

依細分市場分析

依產品分類

預計到2026年，動物保健產品將佔據市場主導地位，市佔率高達64.87%，這主要得益於疾病的高發生率和仿製藥的核准。 2024年6月，美國食品藥物管理局（FDA）批准苯丙醇胺咀嚼片用於治療犬尿失禁，進一步提振了藥品銷售。疫苗對於傳染病控制至關重要，一種新的牛呼吸道疾病（BRD）疫苗正在研發中。用於提高牲畜生產力和飼料轉換率的藥用飼料添加劑市場穩定成長。

依動物類型劃分

2025年，伴侶動物佔了46.1%的市場份額，這得益於寵物飼養率的上升和預防性醫療支出的增加。由於蛋白質需求增加和疾病預防計畫的實施，家畜在2026年成為主導動物，預計2025年至2032年的複合年增長率（CAGR）為5.42%。

依給藥途徑劃分

2024年，在政府疫苗接種計畫的支持下，腸外給藥成為​​疫苗接種和緊急治療的主要途徑。預計到 2026 年，口服藥物的市場份額將達到 47.23%，這主要得益於 Zenrelia 片劑等產品的推動。外用藥物預計將因皮膚病的增加而增長，而氣霧劑療法預計將溫和擴張。

依通路劃分

由於寵物定期體檢和門診就診的頻率較高，預計從 2025 年到 2032 年，獸醫診所的複合年增長率將達到 6.14%，在分銷管道中佔據領先地位。在先進診斷協作的支持下，預計到 2026 年，獸醫院的市佔率將達到 40.99%。藥局則透過改善藥品取得途徑和提供診所內配藥服務而成長。

區域展望

北美市場規模預計在2025年達到189.1億美元，2026年達到201億美元。美國預計將引領市場，到2026年市場規模將達到189.3億美元。歐洲市場規模預計達到120.1億美元，這得益於強而有力的政府福利計畫和製造業產能。亞太地區預計在2026年將達到88億美元，其中中國（15.3億美元）、印度（15.7億美元）和日本（33億美元）將引領市場。拉丁美洲預計在2025年將達到50.2億美元，而海灣合作委員會（GCC）市場在2025年將達到15億美元，這得益於藥物警戒改革和疾病控制計畫。 《全球獸藥市場》報告對全球獸藥產業進行了全面分析，詳細評估了2025年、2026年和2034年的市場規模和價值，並預測了2026年至2034年複合年增長率（CAGR）為6.40%的成長軌跡。本報告考察了獸藥、獸用疫苗和藥用飼料添加劑等關鍵產品類別，並評估了它們在伴侶動物和牲畜中的應用。此外，報告還按給藥途徑（口服、注射、外用、氣霧劑）和分銷管道（獸醫院、動物診所、藥房等）分析了市場。

本報告深入評估了市場驅動因素、限制因素、機會、挑戰和新興趨勢，重點分析了寵物飼養率上升、牲畜疾病負擔加重、抗菌素抗藥性以及基因和細胞療法興起等因素的影響。區域分析涵蓋北美、歐洲、亞太、拉丁美洲以及中東和非洲，並針對美國、英國、德國、法國、中國、印度和日本等主要市場提供國別分析。報告採用經核實的2025年和2026年市場價值數據。本報告重點介紹主要企業，包括碩騰（Zoetis）、默克動物保健（Merck Animal Health）、禮來（Elanco）、勃林格殷格翰（Boehringer Ingelheim）、西瓦（Ceva）、維克（Virbac）和維托奎諾（Vetoquinol），並追踪影響其近期競爭地位的產品審查此外，報告還評估了新冠疫情、監管趨勢、藥物警戒系統和永續發展措施等因素對產業長期發展的影響。

依產品類型劃分，獸藥將在2026年佔據64.87%的市場份額，這反映出市場對傳染病、寄生蟲病和慢性動物疾病治療藥物的高需求。同時，疫苗對於預防疫情爆發至關重要，而飼料添加劑則有助於提高商業農業的生產力。儘管伴侶動物在2025年佔據了46.1%的市場份額，但由於全球蛋白質消費量的增長和生物安全措施的日益嚴格，畜牧業將在2026年佔據主導地位。儘管抗菌素抗藥性、產品召回和監管力度加大等挑戰仍在影響著產品的使用模式，但強大的研發管線、靶向生物製劑獲批數量的增加以及基因和細胞療法的興起正在重塑未來的治療模式。總體而言，持續的創新、預防性藥物的普及以及不斷擴大的獸藥治療基礎設施預計將確保獸藥治療在全球動物保健領域保持重要且不斷增長的地位。

目錄

第一章：引言

第二章：執行摘要

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：關鍵考慮因素

  • 主要國家和地區動物疾病概覽（2025 年）
  • 在開發產品分析
  • 主要國家和地區監管狀況（2025 年）
  • 價格分析
  • 主要國家和地區寵物擁有量統計（2025 年）
  • 新療法與在研療法概述
  • 各種疾病治療方案概述動物疾病
  • 主要公司新產品發布
  • 主要產業趨勢：併購、合作等
  • 新冠疫情對全球獸藥市場的影響

第五章 全球獸藥市場分析：洞察與預測（2021-2034）

  • 市場分析、洞察與預測：依產品分類
    • 獸藥
      • 抗感染藥
      • 抗發炎藥
      • 驅蟲藥
      • 其他
    • 獸用疫苗
      • 滅活​​疫苗
      • 減毒活疫苗疫苗
      • 重組疫苗
      • 其他疫苗
    • 藥用飼料添加劑
      • 抗菌劑
      • 抗球蟲劑
      • 驅蟲藥
      • 其他藥物
  • 市場分析、洞察與預測：依動物類型劃分
    • 伴侶動物
      • 貓
      • 狗
      • 鳥類
      • 其他動物
    • 牲畜
      • 家禽
      • 豬
      • 牛
      • 其他動物
  • 市場分析、洞察與預測：依給藥途徑劃分給藥途徑
    • 口服
    • 注射
    • 局部用藥
    • 氣霧劑
  • 市場分析、洞察與預測：依銷售管道劃分
    • 獸醫院
    • 獸醫診所
    • 藥局和藥局
    • 其他
  • 市場分析、洞察與預測：按地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章：北美獸藥市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 美國
    • 加拿大

第七章：歐洲獸藥市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪的納維亞
    • 其他歐洲國家

第八章：亞太地區獸藥市場分析：洞察與預測（2021-2034）

  • 依國家/地區
    • 中國
    • 日本
    • 印度
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

第九章：拉丁美洲獸藥市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區

第十章：中東與非洲獸藥市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 海灣合作委員會（GCC）國家
    • 南非
    • 其他中東和非洲國家國家/地區

第11章 競爭分析

  • 世界市場佔有率分析(2025年)
  • 企業簡介
    • Zoetis Services LLC
    • Merck Animal Health
    • Elanco
    • Boehringer Ingelheim International GmbH.
    • Ceva
    • Vetoquinol
    • Virbac
    • Phibro Animal Health Corporation
    • Panav Bio Tech.
Product Code: FBI100138

Growth Factors of veterinary therapeutics Market

The global veterinary therapeutics market size was valued at USD 47.25 billion in 2025 and is projected to grow to USD 49.65 billion in 2026, reaching USD 81.59 billion by 2034, registering a CAGR of 6.40% during the forecast period (2026-2034). North America dominated the global veterinary therapeutics market with a 40.02% market share in 2025, supported by high pet ownership rates, strong veterinary healthcare infrastructure, and advanced livestock farming practices.

Veterinary therapeutics includes drugs, vaccines, and medicated feed additives used for disease prevention, treatment, and productivity improvement in both companion and livestock animals. The market plays a critical role in controlling zoonotic diseases, maintaining food safety, and improving animal welfare.

Market Drivers

Rising pet ownership and increasing expenditure on animal health are primary drivers. In the U.S., pet ownership reached 59.8 million dogs and 42.2 million cats in 2024, with average annual household spending of USD 580 for dogs and USD 433 for cats, driving demand for preventive medicines and chronic disease treatments.

Growing livestock production to meet rising global protein demand also contributes to market expansion. According to the World Organization for Animal Health, 77.0% of global livestock is affected by foot-and-mouth disease, increasing demand for vaccines and early disease management. Rising cases of parasitic infections, bovine mastitis, canine parvovirus, and tick-borne diseases further elevate therapeutic demand.

Product launches continue to stimulate growth. In September 2024, Elanco received FDA approval for Zenrelia, a once-daily oral treatment for allergic dermatitis in dogs, reflecting increasing innovation in companion animal therapeutics.

Market Restraints

Product recalls due to adverse reactions and safety issues reduce consumer confidence. In June 2021, the U.K. Veterinary Medicines Directorate recalled Salmovac 400 vaccine produced by CEVA due to safety concerns. In December 2023, Australia recalled Triedlia Auslepto vaccine for dogs after reports of severe adverse reactions, including fatality. Such incidents impact brand reputation and regulatory scrutiny, restraining market growth.

Market Opportunities

R&D investment and regulatory approvals are generating growth opportunities. In April 2024, the FDA approved Pradalex injection for treating bovine and swine respiratory diseases, expanding livestock disease management options. Increased focus on advanced biologics and targeted therapies supports disease control with improved safety profiles.

Growing awareness among farmers and pet owners regarding preventive healthcare also increases adoption of vaccination programs and early diagnostics, expanding market potential across emerging economies.

Market Challenges

Antimicrobial resistance (AMR) presents a major challenge, particularly in low-income agricultural regions where antibiotic misuse is common. In September 2024, the World Organization for Animal Health estimated that antimicrobial resistance could increase global healthcare costs by USD 189.0 billion by 2025. Stricter antimicrobial regulations limit drug availability and affect livestock productivity, challenging therapeutic market growth.

Market Trends

Gene and cell therapies are emerging as innovative treatment approaches in veterinary medicine. In December 2024, Protect Animal Health partnered with Rejuvenate Bio to develop gene therapy PT-401 for treating mitral valve disease in dogs, indicating a shift toward personalized veterinary medicine.

Telemedicine adoption during COVID-19 also increased prescription access and monitoring of chronic conditions, further supporting therapeutic sales.

Segmentation Analysis

By Product

Veterinary drugs dominated with 64.87% share in 2026, driven by high disease prevalence and generic drug approvals. FDA approval of phenylpropanolamine chewable tablets in June 2024 for canine urinary incontinence further strengthened drug sales. Vaccines remain essential for infectious disease control, with new BRD vaccines under development. Medicated feed additives grow steadily to improve livestock productivity and feed efficiency.

By Animal Type

Companion animals accounted for 46.1% share in 2025, supported by rising pet ownership and preventive healthcare spending. Livestock dominated in 2026 due to increased protein demand and disease prevention programs, growing at 5.42% CAGR during 2025-2032.

By Route of Administration

Parenteral routes dominated in 2024 due to vaccine delivery and emergency treatments, supported by government vaccination programs. Oral therapeutics are expected to reach 47.23% share in 2026, driven by products such as Zenrelia tablets. Topical formulations grow due to rising dermatological conditions, while aerosol therapies expand moderately.

By Distribution Channel

Veterinary clinics dominated due to frequent pet checkups and outpatient services, growing at 6.14% CAGR during 2025-2032. Veterinary hospitals are expected to reach 40.99% share in 2026, supported by advanced diagnostic collaborations. Pharmacies grow through improved accessibility and in-clinic dispensing services.

Regional Outlook

North America generated USD 18.91 billion in 2025 and USD 20.10 billion in 2026, led by the U.S. reaching USD 18.93 billion in 2026. Europe reached USD 12.01 billion with strong government welfare programs and manufacturing capabilities. Asia Pacific is projected at USD 8.80 billion in 2026, driven by China (USD 1.53 billion), India (USD 1.57 billion), and Japan (USD 3.30 billion). Latin America reached USD 5.02 billion in 2025, while GCC markets reached USD 1.50 billion in 2025, supported by pharmacovigilance reforms and disease control programs.

Competitive Landscape

Major players including Zoetis, Merck Animal Health, Elanco, Boehringer Ingelheim, Ceva, Vetoquinol, and Virbac lead through product approvals and global expansion. Strategic acquisitions such as Phibro's acquisition of Zoetis' feed additive portfolio in April 2024 strengthen portfolio breadth. Continuous innovation and sustainability initiatives remain central to competitive strategies.

Report Coverage

The veterinary therapeutics market report provides a comprehensive analysis of the global industry with a detailed evaluation of market size and value for 2025, 2026, and 2034, along with the forecast growth trajectory at a CAGR of 6.40% during 2026-2034. The report examines key product categories including veterinary drugs, veterinary vaccines, and medicated feed additives, and evaluates their adoption across companion animals and livestock. It further analyzes the market by route of administration (oral, parenteral, topical, and aerosol) and distribution channels such as veterinary clinics, veterinary hospitals, pharmacies & drug stores, and others.

The study includes an in-depth assessment of market drivers, restraints, opportunities, challenges, and emerging trends, highlighting the impact of rising pet ownership, livestock disease burden, antimicrobial resistance, and the emergence of gene and cell therapies. Regional analysis covers North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa, with country-level insights for major markets including the U.S., U.K., Germany, France, China, India, and Japan, using verified market value data for 2025 and 2026. The report also profiles leading companies such as Zoetis, Merck Animal Health, Elanco, Boehringer Ingelheim, Ceva, Virbac, and Vetoquinol, and tracks recent product approvals, acquisitions, collaborations, and logistics expansions that influence competitive positioning. Additionally, the report evaluates the impact of COVID-19, regulatory trends, pharmacovigilance systems, and sustainability initiatives shaping long-term industry development.

Conclusion

The global veterinary therapeutics market is expanding steadily from USD 47.25 billion in 2025 to USD 49.65 billion in 2026, and is projected to reach USD 81.59 billion by 2034, supported by rising pet ownership, increasing livestock production, and heightened focus on zoonotic disease control and food safety. North America dominated with 40.02% market share in 2025, driven by high pet healthcare spending, strong veterinary infrastructure, and advanced farming technologies, while Asia Pacific and Latin America are gaining momentum due to expanding livestock sectors and improving veterinary access.

Product-wise, veterinary drugs dominate with 64.87% share in 2026, reflecting high treatment demand for infectious, parasitic, and chronic animal diseases, while vaccines remain critical for outbreak prevention and feed additives support productivity in commercial farming. Companion animals accounted for 46.1% share in 2025, but livestock leads in 2026 due to rising global protein consumption and stricter biosecurity practices. Although challenges such as antimicrobial resistance, product recalls, and regulatory tightening continue to affect adoption patterns, strong R&D pipelines, growing approvals for targeted biologics, and the emergence of gene and cell therapies are reshaping future treatment paradigms. Overall, sustained innovation, preventive healthcare adoption, and expanding veterinary infrastructure are expected to keep veterinary therapeutics a vital and growing segment of global animal health.

Segmentation By Product

  • Veterinary Drugs
    • Anti-infectives
    • Anti-inflammatory
    • Parasiticides
    • Others
  • Veterinary Vaccines
    • Inactivated
    • Live Attenuated
    • Recombinant
    • Others
  • Medicated Feed Additives
    • Antimicrobials
    • Anticoccidials
    • Antiparasitics
    • Others

By Route of Administration

  • Oral
  • Parenteral
  • Topical
  • Aerosol

By Distribution Channel

  • Veterinary Hospitals
  • Veterinary Clinics
  • Pharmacies & Drug Stores
  • Others

By Region

  • North America (By Product, By Animal Type, Route of Administration, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Product, By Animal Type, Route of Administration, Distribution Channel, and Country/Sub-Region)
    • U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Product, By Animal Type, By Route of Administration, By Distribution Channel, and Country/Sub-Region)
    • Japan
    • China
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Product, Animal Type, Route of Administration, Distribution Channel, and Country/Sub-Region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Product, Animal Type, Route of Administration, Distribution Channel, and Country/Sub-Region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Overview of Animal Diseases by Key Countries, By Key Countries/ Region, 2025
  • 4.2. Pipeline Analysis
  • 4.3. Regulatory Scenario By Key Countries/ Region, 2025
  • 4.4. Pricing Analysis
  • 4.5. Pet Ownership Statistics, By Key Countries/ Region, 2025
  • 4.6. Snapshot on the Novel & Upcoming Therapies
  • 4.7. Overview of Treatment Plans for Different Animal Diseases
  • 4.8. New Product Launches, By Key Players
  • 4.9. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.10. Impact of COVID-19 on the Global Veterinary Therapeutics Market

5. Global Veterinary Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Product
    • 5.1.1. Veterinary Drugs
      • 5.1.1.1. Anti-infectives
      • 5.1.1.2. Anti-inflammatory
      • 5.1.1.3. Parasiticides
      • 5.1.1.4. Others
    • 5.1.2. Veterinary Vaccines
      • 5.1.2.1. Inactivated
      • 5.1.2.2. Live Attenuated
      • 5.1.2.3. Recombinant
      • 5.1.2.4. Others
    • 5.1.3. Medicated Feed Additives
      • 5.1.3.1. Antimicrobials
      • 5.1.3.2. Anti-coccidials
      • 5.1.3.3. Antiparasitics
      • 5.1.3.4. Others
  • 5.2. Market Analysis, Insights and Forecast - By Animal Type
    • 5.2.1. Companion
      • 5.2.1.1. Feline
      • 5.2.1.2. Canine
      • 5.2.1.3. Avian
      • 5.2.1.4. Others
    • 5.2.2. Livestock
      • 5.2.2.1. Poultry
      • 5.2.2.2. Porcine
      • 5.2.2.3. Bovine
      • 5.2.2.4. Others
  • 5.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.3.1. Oral
    • 5.3.2. Parenteral
    • 5.3.3. Topical
    • 5.3.4. Aerosol
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Veterinary Hospitals
    • 5.4.2. Veterinary Clinics
    • 5.4.3. Pharmacies & Drug Stores
    • 5.4.4. Others
  • 5.5. Market Analysis, Insights and Forecast - Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Veterinary Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Product
    • 6.1.1. Veterinary Drugs
      • 6.1.1.1. Anti-infectives
      • 6.1.1.2. Anti-inflammatory
      • 6.1.1.3. Parasiticides
      • 6.1.1.4. Others
    • 6.1.2. Veterinary Vaccines
      • 6.1.2.1. Inactivated
      • 6.1.2.2. Live Attenuated
      • 6.1.2.3. Recombinant
      • 6.1.2.4. Others
    • 6.1.3. Medicated Feed Additives
      • 6.1.3.1. Antimicrobials
      • 6.1.3.2. Anti-coccidials
      • 6.1.3.3. Antiparasitics
      • 6.1.3.4. Others
  • 6.2. Market Analysis, Insights and Forecast - By Animal Type
    • 6.2.1. Companion
      • 6.2.1.1. Feline
      • 6.2.1.2. Canine
      • 6.2.1.3. Avian
      • 6.2.1.4. Others
    • 6.2.2. Livestock
      • 6.2.2.1. Poultry
      • 6.2.2.2. Porcine
      • 6.2.2.3. Bovine
      • 6.2.2.4. Others
  • 6.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.3.1. Oral
    • 6.3.2. Parenteral
    • 6.3.3. Topical
    • 6.3.4. Aerosol
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Veterinary Hospitals
    • 6.4.2. Veterinary Clinics
    • 6.4.3. Pharmacies & Drug Stores
    • 6.4.4. Others
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Veterinary Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Product
    • 7.1.1. Veterinary Drugs
      • 7.1.1.1. Anti-infectives
      • 7.1.1.2. Anti-inflammatory
      • 7.1.1.3. Parasiticides
      • 7.1.1.4. Others
    • 7.1.2. Veterinary Vaccines
      • 7.1.2.1. Inactivated
      • 7.1.2.2. Live Attenuated
      • 7.1.2.3. Recombinant
      • 7.1.2.4. Others
    • 7.1.3. Medicated Feed Additives
      • 7.1.3.1. Antimicrobials
      • 7.1.3.2. Anti-coccidials
      • 7.1.3.3. Antiparasitics
      • 7.1.3.4. Others
  • 7.2. Market Analysis, Insights and Forecast - By Animal Type
    • 7.2.1. Companion
      • 7.2.1.1. Feline
      • 7.2.1.2. Canine
      • 7.2.1.3. Avian
      • 7.2.1.4. Others
    • 7.2.2. Livestock
      • 7.2.2.1. Poultry
      • 7.2.2.2. Porcine
      • 7.2.2.3. Bovine
      • 7.2.2.4. Others
  • 7.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.3.1. Oral
    • 7.3.2. Parenteral
    • 7.3.3. Topical
    • 7.3.4. Aerosol
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Veterinary Hospitals
    • 7.4.2. Veterinary Clinics
    • 7.4.3. Pharmacies & Drug Stores
    • 7.4.4. Others
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.5.1. Germany
    • 7.5.2. U.K.
    • 7.5.3. France
    • 7.5.4. Italy
    • 7.5.5. Spain
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Veterinary Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Product
    • 8.1.1. Veterinary Drugs
      • 8.1.1.1. Anti-infectives
      • 8.1.1.2. Anti-inflammatory
      • 8.1.1.3. Parasiticides
      • 8.1.1.4. Others
    • 8.1.2. Veterinary Vaccines
      • 8.1.2.1. Inactivated
      • 8.1.2.2. Live Attenuated
      • 8.1.2.3. Recombinant
      • 8.1.2.4. Others
    • 8.1.3. Medicated Feed Additives
      • 8.1.3.1. Antimicrobials
      • 8.1.3.2. Anti-coccidials
      • 8.1.3.3. Antiparasitics
      • 8.1.3.4. Others
  • 8.2. Market Analysis, Insights and Forecast - By Animal Type
    • 8.2.1. Companion
      • 8.2.1.1. Feline
      • 8.2.1.2. Canine
      • 8.2.1.3. Avian
      • 8.2.1.4. Others
    • 8.2.2. Livestock
      • 8.2.2.1. Poultry
      • 8.2.2.2. Porcine
      • 8.2.2.3. Bovine
      • 8.2.2.4. Others
  • 8.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.3.1. Oral
    • 8.3.2. Parenteral
    • 8.3.3. Topical
    • 8.3.4. Aerosol
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Veterinary Hospitals
    • 8.4.2. Veterinary Clinics
    • 8.4.3. Pharmacies & Drug Stores
    • 8.4.4. Others
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.5.1. China
    • 8.5.2. Japan
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Veterinary Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Product
    • 9.1.1. Veterinary Drugs
      • 9.1.1.1. Anti-infectives
      • 9.1.1.2. Anti-inflammatory
      • 9.1.1.3. Parasiticides
      • 9.1.1.4. Others
    • 9.1.2. Veterinary Vaccines
      • 9.1.2.1. Inactivated
      • 9.1.2.2. Live Attenuated
      • 9.1.2.3. Recombinant
      • 9.1.2.4. Others
    • 9.1.3. Medicated Feed Additives
      • 9.1.3.1. Antimicrobials
      • 9.1.3.2. Anti-coccidials
      • 9.1.3.3. Antiparasitics
      • 9.1.3.4. Others
  • 9.2. Market Analysis, Insights and Forecast - By Animal Type
    • 9.2.1. Companion
      • 9.2.1.1. Feline
      • 9.2.1.2. Canine
      • 9.2.1.3. Avian
      • 9.2.1.4. Others
    • 9.2.2. Livestock
      • 9.2.2.1. Poultry
      • 9.2.2.2. Porcine
      • 9.2.2.3. Bovine
      • 9.2.2.4. Others
  • 9.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.3.1. Oral
    • 9.3.2. Parenteral
    • 9.3.3. Topical
    • 9.3.4. Aerosol
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Veterinary Hospitals
    • 9.4.2. Veterinary Clinics
    • 9.4.3. Pharmacies & Drug Stores
    • 9.4.4. Others
  • 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Veterinary Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Product
    • 10.1.1. Veterinary Drugs
      • 10.1.1.1. Anti-infectives
      • 10.1.1.2. Anti-inflammatory
      • 10.1.1.3. Parasiticides
      • 10.1.1.4. Others
    • 10.1.2. Veterinary Vaccines
      • 10.1.2.1. Inactivated
      • 10.1.2.2. Live Attenuated
      • 10.1.2.3. Recombinant
      • 10.1.2.4. Others
    • 10.1.3. Medicated Feed Additives
      • 10.1.3.1. Antimicrobials
      • 10.1.3.2. Anti-coccidials
      • 10.1.3.3. Antiparasitics
      • 10.1.3.4. Others
  • 10.2. Market Analysis, Insights and Forecast - By Animal Type
    • 10.2.1. Companion
      • 10.2.1.1. Feline
      • 10.2.1.2. Canine
      • 10.2.1.3. Avian
      • 10.2.1.4. Others
    • 10.2.2. Livestock
      • 10.2.2.1. Poultry
      • 10.2.2.2. Porcine
      • 10.2.2.3. Bovine
      • 10.2.2.4. Others
  • 10.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.3.1. Oral
    • 10.3.2. Parenteral
    • 10.3.3. Topical
    • 10.3.4. Aerosol
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Veterinary Hospitals
    • 10.4.2. Veterinary Clinics
    • 10.4.3. Pharmacies & Drug Stores
    • 10.4.4. Others
  • 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Zoetis Services LLC
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Merck Animal Health
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Elanco
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Boehringer Ingelheim International GmbH.
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Ceva
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Vetoquinol
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. Virbac
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Phibro Animal Health Corporation
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Panav Bio Tech.
      • 11.2.9.1. Overview
      • 11.2.9.2. Products
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 2: Global Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Veterinary Drugs, 2021-2034
  • Table 3: Global Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Veterinary Vaccines, 2021-2034
  • Table 4: Global Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Medicated Feed Additives, 2021-2034
  • Table 5: Global Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Animal Type, 2021-2034
  • Table 6: Global Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Companion, 2021-2034
  • Table 7: Global Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Livestock, 2021-2034
  • Table 8: Global Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration 2021-2034
  • Table 9: Global Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 10: Global Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 11: North America Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 12: North America Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Veterinary Drugs, 2021-2034
  • Table 13: North America Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Veterinary Vaccines, 2021-2034
  • Table 14: North America Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Medicated Feed Additives, 2021-2034
  • Table 15: North America Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Animal Type, 2021-2034
  • Table 16: North America Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Companion, 2021-2034
  • Table 17: North America Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Livestock, 2021-2034
  • Table 18: North America Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration 2021-2034
  • Table 19: North America Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 20: North America Veterinary Therapeutics Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 21: Europe Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 22: Europe Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Veterinary Drugs, 2021-2034
  • Table 23: Europe Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Veterinary Vaccines, 2021-2034
  • Table 24: Europe Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Medicated Feed Additives, 2021-2034
  • Table 25: Europe Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Animal Type, 2021-2034
  • Table 26: Europe Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Companion, 2021-2034
  • Table 27: Europe Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Livestock, 2021-2034
  • Table 28: Europe Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration 2021-2034
  • Table 29: Europe Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 30: Europe Veterinary Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 31: Asia Pacific Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 32: Asia Pacific Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Veterinary Drugs, 2021-2034
  • Table 33: Asia Pacific Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Veterinary Vaccines, 2021-2034
  • Table 34: Asia Pacific Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Medicated Feed Additives, 2021-2034
  • Table 35: Asia Pacific Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Animal Type, 2021-2034
  • Table 36: Asia Pacific Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Companion, 2021-2034
  • Table 37: Asia Pacific Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Livestock, 2021-2034
  • Table 38: Asia Pacific Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration 2021-2034
  • Table 39: Asia Pacific Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 40: Asia Pacific Veterinary Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 41: Latin America Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 42: Latin America Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Veterinary Drugs, 2021-2034
  • Table 43: Latin America Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Veterinary Vaccines, 2021-2034
  • Table 44: Latin America Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Medicated Feed Additives, 2021-2034
  • Table 45: Latin America Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Animal Type, 2021-2034
  • Table 46: Latin America Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Companion, 2021-2034
  • Table 47: Latin America Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Livestock, 2021-2034
  • Table 48: Latin America Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration 2021-2034
  • Table 49: Latin America Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 50: Latin America Veterinary Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 51: Middle East & Africa Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 52: Middle East & Africa Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Veterinary Drugs, 2021-2034
  • Table 53: Middle East & Africa Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Veterinary Vaccines, 2021-2034
  • Table 54: Middle East & Africa Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Medicated Feed Additives, 2021-2034
  • Table 55: Middle East & Africa Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Animal Type, 2021-2034
  • Table 56: Middle East & Africa Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Companion, 2021-2034
  • Table 57: Middle East & Africa Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Livestock, 2021-2034
  • Table 58: Middle East & Africa Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration 2021-2034
  • Table 59: Middle East & Africa Veterinary Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 60: Middle East & Africa Veterinary Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Veterinary Therapeutics Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Veterinary Therapeutics Market Value Share (%), by Product, 2025 & 2034
  • Figure 3: Global Veterinary Therapeutics Market Value Share (%), by Animal Type, 2025 & 2034
  • Figure 4: Global Veterinary Therapeutics Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 5: Global Veterinary Therapeutics Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 6: Global Veterinary Therapeutics Market Value (USD billion), by Region, 2025 & 2034
  • Figure 7: North America Veterinary Therapeutics Market Value (USD billion), by Product, 2025 & 2034
  • Figure 8: North America Veterinary Therapeutics Market Value Share (%), by Product, 2025
  • Figure 9: North America Veterinary Therapeutics Market Value (USD billion), by Animal Type, 2025 & 2034
  • Figure 10: North America Veterinary Therapeutics Market Value Share (%), by Animal Type, 2025
  • Figure 11: North America Veterinary Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 12: North America Veterinary Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 13: North America Veterinary Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 14: North America Veterinary Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 15: North America Veterinary Therapeutics Market Value (USD billion), By Country, 2025 & 2034
  • Figure 16: North America Veterinary Therapeutics Market Value Share (%), By Country, 2025
  • Figure 17: Europe Veterinary Therapeutics Market Value (USD billion), by Product, 2025 & 2034
  • Figure 18: Europe Veterinary Therapeutics Market Value Share (%), by Product, 2025
  • Figure 19: Europe Veterinary Therapeutics Market Value (USD billion), by Animal Type, 2025 & 2034
  • Figure 20: Europe Veterinary Therapeutics Market Value Share (%), by Animal Type, 2025
  • Figure 21: Europe Veterinary Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 22: Europe Veterinary Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 23: Europe Veterinary Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 24: Europe Veterinary Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 25: Europe Veterinary Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 26: Europe Veterinary Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 27: Asia Pacific Veterinary Therapeutics Market Value (USD billion), by Product, 2025 & 2034
  • Figure 28: Asia Pacific Veterinary Therapeutics Market Value Share (%), by Product, 2025
  • Figure 29: Asia Pacific Veterinary Therapeutics Market Value (USD billion), by Animal Type, 2025 & 2034
  • Figure 30: Asia Pacific Veterinary Therapeutics Market Value Share (%), by Animal Type, 2025
  • Figure 31: Asia Pacific Veterinary Therapeutics Market Value (USD billion),by Route of Administration, 2025 & 2034
  • Figure 32: Asia Pacific Veterinary Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 33: Asia Pacific Veterinary Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 34: Asia Pacific Veterinary Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 35: Asia Pacific Veterinary Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 36: Asia Pacific Veterinary Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 37: Latin America Veterinary Therapeutics Market Value (USD billion), by Product, 2025 & 2034
  • Figure 38: Latin America Veterinary Therapeutics Market Value Share (%), by Product, 2025
  • Figure 39: Latin America Veterinary Therapeutics Market Value (USD billion), by Animal Type, 2025 & 2034
  • Figure 40: Latin America Veterinary Therapeutics Market Value Share (%), by Animal Type, 2025
  • Figure 41: Latin America Veterinary Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 42: Latin America Veterinary Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 43: Latin America Veterinary Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 44: Latin America Veterinary Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 45: Latin America Veterinary Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 46: Latin America Veterinary Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 47: Middle East & Africa Veterinary Therapeutics Market Value (USD billion), by Product, 2025 & 2034
  • Figure 48: Middle East & Africa Veterinary Therapeutics Market Value Share (%), by Product, 2025
  • Figure 49: Middle East & Africa Veterinary Therapeutics Market Value (USD billion), by Animal Type, 2025 & 2034
  • Figure 50: Middle East & Africa Veterinary Therapeutics Market Value Share (%), by Animal Type, 2025
  • Figure 51: Middle East & Africa Veterinary Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 52: Middle East & Africa Veterinary Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 53: Middle East & Africa Veterinary Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 54: Middle East & Africa Veterinary Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 55: Middle East & Africa Veterinary Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 56: Middle East & Africa Veterinary Therapeutics Market Value Share (%), By Country/ Sub-region, 2025

Figure 57: Global Veterinary Therapeutics Market Share (%), By Company, 2025